Global pharma industry supplier ACG on Tuesday said it will invest Rs 600 crore to build Asia's largest capsules manufacturing unit near Aurangabad in Maharashtra.
Cardiac medicines accounted for the highest volumes in 2020. Despite the burden of diabetes rising, its share in volumes was low; however, its share in total value was higher
Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. The company selling prescription drugs and medical devices will keep Johnson & Johnson as its name, the company said Friday. The new consumer health company will house brands including Neutrogena, Aveeno, Tylenol, Listerine, Johnson's, and Band-Aid. A name was not disclosed for the new company. Details are sparse, but the company expect the split to occur in the next two years. The announcement comes just days after General Electric said that it plans to split into three separate companies.
With six Indian pharma companies working to manufacture antiviral pill Molnupiravir, healthcare experts say the game-changing drug will give India an effective and affordable weapon
According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."
The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring
Stock trading at the highest discount to ten-year valuation averages, as brokerages favour its US specialty portfolio.
Hospital industry sources claim they want assurance on shelf life of imported vaccines
Led by drugs and pharmaceuticals, India's exports from special economic Zones (SEZs) rose by 41.5 per cent on a year-on-year (YoY) basis to Rs 2.15 lakh crore in Q1FY22
Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH)
The pandemic push will lead to an 11 per cent annual growth for the pharma sector over the next two years and help it surpass USD 60 billion from around USD 45 billion in FY21, according to a report.
Resolution of supply chain issues, defensive buying and index inclusion are triggers
Approach drug regulator, seeking permission to conduct clinical trials
Union Health Minister Mansukh Mandaviya on Thursday urged the pharma industry to consider domestic manufacturing of medicines which are soon going to be off patent under Atmanirbhar Bharat
In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector
Korea's bio pharmaceutical exports rose from 9th to 7th in the world last year
A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors
These are scheduled drugs (or ones that are under price control) and low priced
Govt and vaccine makers should be transparent
The COVID-19 lockdown witnessed a sharp spike in counterfeiting incidents in pharmaceutical products, especially PPE kits and sanitisers, as per a report by industry body ASPA. Counterfeiting incidents in India have risen "rapidly in the last few years, with a 20 per cent growth from January 2018 to December 2020, the Authentication Solution Providers' Association (ASPA) said. The top five sectors which have been most affected by counterfeiting are -- alcohol, tobacco, FMCG packaged goods, currency and pharmaceuticals. They together constitute more than 84 per cent of the total counterfeiting incidents reported. Within the last month, there have been a number of cases reported of fake COVID-19 medication. "Counterfeiters are taking advantage of the high demand for medicines, health supplements, safety products, hygiene products and other essentials created due to the COVID crisis and contaminating the market by selling fake and sub-standard products," said the report, titled 'The .